be_ixf;ym_202012 d_02; ct_100

Select Page

Nick Tate

Nick TateNick Tate Senior Editorial Manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.

Nick Tate is the senior editorial manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.

As a best-selling author, seasoned journalist and TV commentator specializing in health care, finance and biotech, Nick is all about big ideas and innovations — always keeping his followers informed on the next big thing.

His work has appeared in The Miami Herald, The Atlanta Journal-Constitution, South Florida Business Journal, Newsmax Magazine, South Florida Sun Sentinel, Boston Herald, and on Newsmax TV and the Al Jazeera network.

His top-selling book, the ObamaCare Survival Guide, was on the Publishers Weekly and The New York Times best-sellers lists for 22 weeks — reaching No. 1 on The Times list for paperback advice books.

Tate also co-authored DaVinci’s Baby Boomer Survival Guide: Live, Prosper, and Thrive in Your Retirement. And he published two other books — the Encyclopedia of Natural Healing and The Sick Building Syndrome — following a year-long journalism fellowship at the Harvard School of Public Health.

Tate’s three-decades-long commitment to keeping the public well-informed is why Banyan Hill Publishing recruited him in 2018 to join Paul Mampilly’s team. You can now read Nick’s weekly analysis in Bold Profits Daily as he guides over 130,000 readers on the best ways to grow their wealth.

Nick Tate's Articles

Precision Medicine Alert: 2 Plays for 175% Growth - Investing in one precision medicine treatment (or the HUGE market) can lead you to the next medical fortune — like the early investors of the human genome, penicillin or any vaccine.
3D-Printing Stocks: Biggest Opportunity of the Year - 3D printing is skyrocketing! Now it’s remaking hospitals. Here are the top stocks to buy for the Fourth Industrial Revolution upgrade.
10X Your Pink DNA Dollars with 1 Catalyst - A new “targeted therapy” treatment — a catalyst for its stock — is a great move for the $217 billion precision medicine market.
America 2.0 RX: Double Buy for 3D-Printed Bones - 3D printing + precision medicine = a game-changing solution for broken bones and big profits for you. Here are the two top buys (plus a bonus) just for you.
Bold Profits Buy for $51 Billion Era of New Medicine - Buy this ETF to profit from the world’s first “liquid biopsy” DNA blood test to diagnose cancer. And find out how to position yourself precisely ahead of the biggest winners in the Main Street bull market.
America 2.0’s “Living Tech” vs. Cancer: Invest Now - NEW breakthrough! Living technology is an America 2.0 sector that will not only lead you to some of the biggest investment gains out there, but it could change the world.
One 3D Stock You’ll Want Before 2021 - Supply and demand are being met with this remarkable one-two mega trend punch. Here’s the No. 1 stock to buy before it soars next year.
3D-Printing + Biotech Breakthrough = 5X Gains for You - A new biotech breakthrough is taking 3D printing to the next level. Here are three ways to profit from the top America 2.0 picks this year.
Tesla’s In! Invest in 3D-Printing Breakthrough for 300% by 2025 - Tesla has just made a 3D-printing breakthrough that will be a game changer for the auto industry. It’s the latest advance in 3D printing, an America 2.0 mega trend on track to become a global industry projected to rise 300% by 2025.
3D printing Take 10X Gains in 5 Years With the 3D-Printing Mega Trend! - 3D printing is on a tear, with the global market set to rise 900% by 2025. Here’s your best way to profit from this America 2.0 mega trend and boost your gains 10X.

Newsletter Sign Up




I am up $20,070 in closed positions from Feb. 18 through March 7.

- Bob Rowe

I started your system in December … I am ahead $29,000 … I put total faith in you and your system and it has worked for me very nicely. Thanks again I sure like your humble approach about this whole thing

- Dale Leiffer

I have made a little over $4,000 while being cautious.

- Chuck Goss